Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Trial Evaluating the Efficacy and Safety of Nivolumab Monotherapy for Incurable Recurrent or Metastatic Olfactory Neuroblastoma.

NCT07100704 is registered in ClinicalTrials.gov with National Cancer Center Hospital East as lead sponsor.

NCT NCT07100704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07100704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Trial Evaluating the Efficacy and Safety of Nivolumab Monotherapy for Incurable Recurrent or Metastatic Olfactory Neuroblastoma.
Lead sponsor
National Cancer Center Hospital East
Phase
Phase 2
Overall status
Recruiting
Start date
April 15, 2025
Completion date
October 14, 2028
Enrollment
14 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent/ metastatic olfactory neuroblastoma